Mark Covid’s treatment pill wins FDA panel award

Clinical trials have reduced the risk of hospitalization or death by 30% for the most vulnerable and unvaccinated volunteers within five days of the onset of symptoms. It seems to be much less effective than Pfizer’s pill, which has been shown to reduce the risk by 89%. Monoclonal antibody treatments have been shown to reduce the risk of hospitalization or death by at least 70%.

If the FDA authorizes the use of molnupiravir, supplies may be initially restricted.

In addition, the compact time limit for taking the pills can be challenging. Medication should be given within five days of the onset of symptoms and should be taken as 40 pills in five days.

Patients should be checked for coronary heart disease and see a doctor. However, it can often take days to get a PCR test, and in some parts of the country it is difficult to get a test that returns the results within 15 minutes. In addition, many people do not have a regular doctor’s prescription.

The Biden administration has ordered over $ 700 million per course of treatment for 3.1 million people. Mercury is expected to deliver those pills by February. Pfizer, on the other hand, is expected to supply enough pills to cover 300,000 people in the United States before the end of February.

One question that remains to be seen is how many eligible Americans will refuse to take their new pills. In a public opinion poll released this week, half of the unvaccinated adults – the main group expected to need the pills – said they would not take FDA-approved antiviral pills if they were infected with CVD.

Several committee members raised questions about the safety of the pill. The treatment works by injecting errors into the genes of the virus. Some scientists say that there is a theoretical risk for cell proliferation and birth defects or long-term cancer.

Dr. Amy Hodewanek, a senior medical officer in the FDA, said at the meeting that “the overall risk of change in humans is low.”

Leave a Comment